Chase AIPricingFAQs
Display currency
Loading news…

GliaPharm

ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 HighHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals.
Geneva, Geneve, Switzerland Founded 2016 1-10 employees For Profit

GliaPharm is a Swiss-based biotechnology company that develops treatments for neurological and psychiatric disorders.

Total Funding
Available in Pro
Last Funding
Available in Pro
Acquisitions
0
Monthly Visits
Available in Pro
Contacts
0
Patents
13
2 trademarks

Company Details

Funding & Financials

Pro
Total funding
Funding rounds
Last funding
Last funding type
Last funding date
Funding status
Total equity funding
Revenue range

IPO & Stock

IPO status
Private

Web Traffic

Pro
Monthly visits
Global traffic rank
6-mo avg visits
Visit duration (s)
Pages / visit
Bounce rate
Rank change (mo)

Technology & IP

Active technologies
43
Patents granted
13
Trademarks
2
Top patent class
Medical Or Veterinary Science; Hygiene
IT spend
$370K

Company Info

Founded
2016
Employees
1-10
Operating status
Active
Company type
For Profit
Org types
company
Founders
3
News articles
10
HQ
Geneva, Geneve, Switzerland
Region
Europe, Middle East, and Africa (EMEA)

Signals & Scores

Heat score
High
Growth score
Low
Trend (7d)
2.2
Trend (30d)
1
Trend (90d)
0.6

Key People at GliaPharm

Chief Scientific Officer, Co-founder
Co-CEO, OPERATING & TECHNOLOGY & Co-Founder
CO-CEO, FINANCE & BUSINESS DEVELOPMENT, CO-FOUNDER

Explore 200,000+ acquisitions — free

Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.

Explore all acquisitions

Recent News related to GliaPharm

Loading news…

FAQs about GliaPharm

People who checked this page also checked these

Browse the full Acquirezy directory.
GliaPharm - Company Profile, Full Acquisitions List, Funding and Investments